NYSE : NVS
Novartis AG — Key statistics
Healthcare · Drug Manufacturers - General · Switzerland
Last price 160.79 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 306.70B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 304.56B |
| Enterprise Value | 345.07B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 27, 2026 |
| Ex-Dividend Date | Mar 11, 2026 |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 1.89B |
| Shares Change (YoY) | -2.76% |
| Shares Change (QoQ) | -0.47% |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 43.86% |
| Float | 1.84B |
Ratios
| Measure | Value |
|---|
| PE Ratio | 30.28 |
| Forward PE | 16.61 |
| PS Ratio | 5.29 |
| Forward PS | 5.00 |
| PB Ratio | 8.07 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 19.36 |
| P/OCF Ratio | 17.50 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 34.26 |
| EV / Sales | 5.99 |
| EV / EBITDA | 14.28 |
| EV / EBIT | 17.63 |
| EV / FCF | 21.95 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.88 |
| Quick Ratio | 0.58 |
| Debt / Equity | 1.29 |
| Debt / EBITDA | 1.98 |
| Debt / FCF | 3.09 |
| Interest Coverage | 12.36 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 24.33% |
| Return on Assets (ROA) | 10.86% |
| Return on Invested Capital (ROIC) | 19.26% |
| Return on Capital Employed (ROCE) | 23.04% |
| Weighted Average Cost of Capital (WACC) | 6.24% |
| Revenue Per Employee | $762,140 |
| Profits Per Employee | $133,272 |
| Employee Count | 75,267 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 2.27 |
Taxes
| Measure | Value |
|---|
| Income Tax | 2.63B |
| Effective Tax Rate | 20.80% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.47 |
| 52-Week Price Change | +30.48% |
| 50-Day Moving Average | 148.46 |
| 200-Day Moving Average | 151.90 |
| Relative Strength Index (RSI) | 69.61 |
| Average Volume (20 Days) | 2,070,633 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.59M |
| Short Previous Month | 5.20M |
| Short % of Shares Out | 0.30% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.01 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 57.36B |
| Gross Profit | 43.14B |
| Operating Income | 19.49B |
| Pretax Income | 12.64B |
| Net Income | 10.03B |
| EBITDA | 24.07B |
| EBIT | 19.49B |
| Earnings Per Share (EPS) | $5.34 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 8.87B |
| Total Debt | 48.31B |
| Net Cash | -39.44B |
| Net Cash Per Share | -$20.88 |
| Equity (Book Value) | 37.56B |
| Book Value Per Share | 19.71 |
| Working Capital | -3.78B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 17.33B |
| Capital Expenditures | -1.67B |
| Depreciation & Amortization | 4.57B |
| Net Borrowing | 16.19B |
| Free Cash Flow | 15.66B |
| FCF Per Share | $8.29 |
Margins
| Measure | Value |
|---|
| Gross Margin | 75.21% |
| Operating Margin | 33.98% |
| Pretax Margin | 22.04% |
| Profit Margin | 17.49% |
| EBITDA Margin | 41.95% |
| EBIT Margin | 33.98% |
| FCF Margin | 27.29% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | $3.08 |
| Dividend Yield | 1.91% |
| Dividend Growth (YoY) | 18.68% |
| Years of Dividend Growth | 6 |
| Payout Ratio | 58.18% |
| FCF Payout Ratio | 37.17% |
| Buyback Yield | 2.76% |
| Shareholder Yield | 4.67% |
| Earnings Yield | 3.30% |
| FCF Yield | 5.16% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $154.80 |
| Price Target Difference | -4.16% |
| Analyst Consensus | Hold |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | 4.79% |
| EPS Growth Forecast (3Y) | 6.65% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | May 11, 2000 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 3.56 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |